диссертации / 30

composition in patients with HIV infection. // J Acquir Immune Defic Syndr. -

2000; 23: pp. 35–43.

103.Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. // J Biol Chem. - 2000; 275: pp. 20251-

104.Mynarcik DC, McNurlan MA, Steigbigel RT et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptors in HIV lipodystrophy. // J Acquir Immune Defic Syndr.- 2000; 25: pp. 312-321.

105.Ngeh J, Gupta S. Clamydia pneumoniae and Atherosclerosis: Causal or Coincidental Link? // ASM News. - 2000; 66: pp.732-7.

106.Nixon DE, Alan L, Landay LA. Biomarkers of immune dysfunction in HIV. // Curr Opin HIV AIDS.- 2010; 5(6): pp. 498–503

107.Noor MA, Lo JC, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. // AIDS. - 2001; 15: pp. 11–8.

108.Noor MA, Parker RA, O'Mara E et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. // AIDS. - 2004; 18(16): pp. 2137-44.

109.Obel N, Thomsen HF, Kronborg G et al. Ischemic heart disease in HIVinfected and HIV-uninfected individuals: a population-based cohort study. // Clin Infect Dis. - 2007; 44: pp. 1625-1631.

110.Oko F, Naito T, Oike M et al. Correlation between HIV disease and lipid metabolism in antiretroviral – naïve HIV – infected patients in Japan. // Journal of Infection and Chemotherapy. – 2012; 18 (1): pp. 17-21.

HIVinfected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. // Circulation. - 1999; 100: pp. 700–5.

151

113.Phillips AN, Carr A, Neuhaus J еt al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. // Antivir Ther. - 2008; 13: pp.177–187.

114.Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. // AIDS. - 2000; 14: pp. 51–7.

115.Rasmussen OW, Ingerslev J, Hermansen K. Plasma levels of von Willebrand factor in non-insulin-dependent diabetes mellitus are influenced by dietary monounsaturated fatty acids. Thrombosis Research, 1995, 4 (77): pp. 347–356.

116.Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. // Circulation. - 1998; 98: pp. 731–3.

117.Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. // N Engl J Med. -1997; 336: pp. 973–9.

118.Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? // Arterioscler Thromb Vasc Biol. - 2006; 26: pp. 2421-2432.

119.Savès M, Chêne G, Ducimetière P et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. // Clin Infect Dis. - 2003; 37: pp. 292–298.

120.Segerer S, Bogner JR, Walli R et al. Hyperlipidemia under treatment with proteinase inhibitors. // Infection. - 1999; 27: pp. 77–81.

121.Stec JJ, Silbershatz H, Tofler GH et al. Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population. Circulation. - 2000; 102: pp. 1634-1638

122.Sterling TR, Vlahov D, Astemborski J et al. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. // N Engl J Med - 2001; 344: pp. 720-725

152

123.Subramanian S, Tawakol A, Burdo TH et al. Arterial Inflammation in Patients with HIV. // JAMA. - 2012; 308(4): pp. 379-386

124.Sullivan AK, Feher MD, Nelson MR et al. Marked hypertriglyceridaemia associated with ritonavir therapy. // AIDS. - 1998; 12: pp. 1393–4.

125.Teto G, Kanmogne GD, Torimiro JN et al. Lipid Peroxidation and Total Cholesterol in HAART-Naïve Patients Infected with Circulating Recombinant Forms of Human Immunodeficiency Virus Type-1 in Cameroon. // PLoS ONE. – 2013; 8(6): e65126.

126.Tewar CR, Nijhawan VS, Mishra MN et al. Prevalence of Helicobacter pylori, cytomegalovirus, and Chlamydia pneumoniae immunoglobulin seropositivity in coronary artery disease patients and normal individuals in North Indian population. // MJAFI. - 2012; 68: pp. 53–57.

127.The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. // Lancet. - 2012; 379 (9822): pp.1214 – 1224.

128.Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. // Curr Opin Lipidol. - 2007;18(5): pp. 561–5.

129.Torriani FJ, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviralnaive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. // J Am Coll Cardiol.- 2008; 52: pp. 569-576.

130.Toss H, Lindahl B, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. // N Engl J Med. - 2000; 343: pp.1139–1147

131.Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human

153

immunodeficiency virus disease. // J Clin Endocrinol Metab. - 2007; 92: pp.

2506-2512.

132.Triant VA. HIV and Cardiovascular Disease. // HIV/AIDS Annual Update,

2010.

133.Tuomisto K, Jousilahti P, Sundvall J et al. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. // Thromb Haemost. - 2006; 95(3): pp.511-8.

134.Vatier C, Leroyer S, Quette J et al. HIV protease inhibitors differently affect human subcutaneos and visceral fat: they induce IL – 6 production and alter lipid storage capacity in subcutaneous but not visceral adipose tissue explants. // Antiviral Therapy. - 2008; 13(4): A3 (abstract № O-02).

135.Volpato S, Guralnik JM, Ferrucci L et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. // Circulation. - 2001; 103(7): pp. 947-53.

136.Vonderen, van, MGA, Hassink EAM, van Agtmael MA et al. Increase in Carotid Artery Intima-Media Thickness and Arterial Stiffness but Improvement in Several Markers of Endothelial Function after Initiation of Antiretroviral Therapy. // JID. - 2009; 199: pp. 1186 – 1194.

137.Wheeler JG, Juzwishin KD, Eiriksdottir G et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. // PLoS Med.- 2005; 2(3):e76

138.White AJ. Review Mitochondrial toxicity and HIV therapy. // Sex Transm Infect. - 2001; 77(3): pp. 158-73.

154